<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="case-report"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cureus</journal-id><journal-id journal-id-type="iso-abbrev">Cureus</journal-id><journal-id journal-id-type="issn">2168-8184</journal-id><journal-title-group><journal-title>Cureus</journal-title></journal-title-group><issn pub-type="epub">2168-8184</issn><publisher><publisher-name>Cureus</publisher-name><publisher-loc>Palo Alto (CA)</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11681799</article-id><article-id pub-id-type="doi">10.7759/cureus.74657</article-id><article-categories><subj-group subj-group-type="heading"><subject>Neurology</subject></subj-group><subj-group><subject>Internal Medicine</subject></subj-group><subj-group><subject>Pulmonology</subject></subj-group></article-categories><title-group><article-title>Post-infectious Inflammatory Motor-Predominant Neuropathy Following Mycoplasma Infection</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Muacevic</surname><given-names>Alexander</given-names></name></contrib><contrib contrib-type="editor"><name><surname>Adler</surname><given-names>John R</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Shashidhara</surname><given-names>Anush K</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Bala</surname><given-names>Sithu</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Browne</surname><given-names>Stefan</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Cliff</surname><given-names>Michael</given-names></name><xref rid="aff-2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Mallia</surname><given-names>Patrick</given-names></name><xref rid="aff-3" ref-type="aff">3</xref></contrib></contrib-group><aff id="aff-1">
<label>1</label>
General Internal Medicine, Royal Free London NHS Foundation Trust, London, GBR </aff><aff id="aff-2">
<label>2</label>
Neurology, Royal Free London NHS Foundation Trust, London, GBR </aff><aff id="aff-3">
<label>3</label>
Respiratory Medicine, Royal Free London NHS Foundation Trust, London, GBR </aff><author-notes><corresp id="cor1">
Sithu Bala <email>sithu.bala@nhs.net</email>
</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>28</day><month>11</month><year>2024</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>11</month><year>2024</year></pub-date><volume>16</volume><issue>11</issue><elocation-id>e74657</elocation-id><history><date date-type="accepted"><day>28</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2024, Shashidhara et al.</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Shashidhara et al.</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri xlink:href="https://www.cureus.com/articles/320289-post-infectious-inflammatory-motor-predominant-neuropathy-following-mycoplasma-infection">This article is available from https://www.cureus.com/articles/320289-post-infectious-inflammatory-motor-predominant-neuropathy-following-mycoplasma-infection</self-uri><abstract><p>We present a case of a 37-year-old gentleman diagnosed with post-infectious Guillain-Barr&#x000e9; syndrome (GBS) secondary to a Mycoplasma pneumoniae infection. This case highlights the subclinical presentation of neurological symptoms, often overlooked as a complication of M. pneumoniae infection. The patient exhibited significant neurological deficits following initial respiratory symptoms, demonstrating the need for awareness of these potential extrapulmonary complications in clinical practice.</p></abstract><kwd-group kwd-group-type="author"><kwd>immune</kwd><kwd>infection</kwd><kwd>motor</kwd><kwd>pneumonia</kwd><kwd>polyneuropathy</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Mycoplasma pneumoniae is a notable pathogen responsible for respiratory infections, particularly atypical pneumonia [<xref rid="REF1" ref-type="bibr">1</xref>], with epidemics occurring approximately every four to seven years [<xref rid="REF2" ref-type="bibr">2</xref>].&#x000a0;This bacterium is implicated in approximately 20% of cases of community-acquired pneumonia and has also been implicated in some hospital-based epidemics. Respiratory infection occurs mainly in children and young adults and is often seen in closed community settings, such as schools, universities, nursing homes, and military bases [<xref rid="REF2" ref-type="bibr">2</xref>].</p><p>M. pneumoniae has been associated with severe extrapulmonary manifestations, affecting multiple organs, including neurological disorders such as meningitis, meningoencephalitis, and polyneuropathy [<xref rid="REF3" ref-type="bibr">3</xref>].&#x000a0;Guillain-Barr&#x000e9; syndrome (GBS), is the most common and most severe acute motor neuropathy in the world, affecting around 100,000 people annually [<xref rid="REF4" ref-type="bibr">4</xref>]. GBS represents a spectrum of disease with a variety of subtypes and disease processes, with the classic subtype being acute inflammatory demyelinating polyneuropathy [<xref rid="REF5" ref-type="bibr">5</xref>,<xref rid="REF6" ref-type="bibr">6</xref>].</p></sec><sec sec-type="cases"><title>Case presentation</title><p>A 37-year-old Caucasian male presented to the Emergency Department with a two-week history of productive cough, shortness of breath, and fever and a shorter, one-day history of difficulty passing urine. He was a non-smoker with no significant medical history or prior respiratory conditions. His recent travel history included a visit to an urban seaside town in Spain, with no reported rashes or insect bites and no known unwell contacts.</p><p>Upon admission, the patient was diagnosed with multifocal pneumonia, confirmed as M. pneumoniae positive via serology (IgG and IgM), with the rest of his blood tests shown in Table <xref rid="TAB1" ref-type="table">1</xref>. A chest x-ray (Figure <xref rid="FIG1" ref-type="fig">1</xref>) showed left lower lobe consolidation with some volume loss and tenting of the hemidiaphragm and faint opacification within the right lower lobe. The D-dimer level was elevated to 977ng/mL, prompting the request for a computed tomography pulmonary angiogram (Figure <xref rid="FIG2" ref-type="fig">2</xref>), which showed no evidence of pulmonary embolism but revealed multi-focal consolidation with airway mucus plugging. There was also diffuse nodularity,&#x000a0;and a mild degree of ground-glass change within both lower lobes, worse within the left.</p><table-wrap position="float" id="TAB1"><label>Table 1</label><caption><title>Laboratory analysis of blood tests at admission</title></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Test&#x000a0;</td><td rowspan="1" colspan="1">Value&#x000a0;</td><td rowspan="1" colspan="1">Normal laboratory range&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Hemoglobin&#x000a0;</td><td rowspan="1" colspan="1">140&#x000a0;</td><td rowspan="1" colspan="1">135-170g/L&#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">White cell count&#x000a0;</td><td rowspan="1" colspan="1">12.8&#x000a0;</td><td rowspan="1" colspan="1">3.5-11x10<sup>9</sup>/L&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Platelets&#x000a0;</td><td rowspan="1" colspan="1">483&#x000a0;</td><td rowspan="1" colspan="1">140-400 x10<sup>9</sup>/L&#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Neutrophils&#x000a0;</td><td rowspan="1" colspan="1">11.0&#x000a0;</td><td rowspan="1" colspan="1">1.7-7.5x10<sup>9</sup>/L&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Lymphocytes&#x000a0;</td><td rowspan="1" colspan="1">1.0&#x000a0;</td><td rowspan="1" colspan="1">1-4x10<sup>9</sup>/L&#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">C-reactive protein&#x000a0;</td><td rowspan="1" colspan="1">54&#x000a0;</td><td rowspan="1" colspan="1">0-5mg/L&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Sodium&#x000a0;</td><td rowspan="1" colspan="1">132&#x000a0;</td><td rowspan="1" colspan="1">133-146mmol/L&#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Potassium&#x000a0;</td><td rowspan="1" colspan="1">4.3&#x000a0;</td><td rowspan="1" colspan="1">3.5-5.3mmol/L&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Urea&#x000a0;</td><td rowspan="1" colspan="1">4.3&#x000a0;</td><td rowspan="1" colspan="1">2.1-7.1mmol/L&#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Creatinine&#x000a0;</td><td rowspan="1" colspan="1">74&#x000a0;</td><td rowspan="1" colspan="1">59-104 microgram/L&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Mycoplasma IgG&#x000a0;</td><td rowspan="1" colspan="1">Positive&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Mycoplasma IgM&#x000a0;</td><td rowspan="1" colspan="1">Positive&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table></table-wrap><fig position="anchor" fig-type="figure" id="FIG1"><label>Figure 1</label><caption><title>Chest radiograph at initial presentation showing left lower lobe consolidation</title></caption><graphic xlink:href="cureus-0016-00000074657-i01" position="float"/></fig><fig position="anchor" fig-type="figure" id="FIG2"><label>Figure 2</label><caption><title>CT pulmonary angiogram showing left lower lobe and to a lesser degree right lower lobe consolidation with airway mucus plugging, diffuse nodularity, and a mild degree of ground-glass change within both lower lobes, worse in the left.</title></caption><graphic xlink:href="cureus-0016-00000074657-i02" position="float"/></fig><p>Upon presentation, a post-void bladder scan revealed a bladder volume of 440 milliliters. Subsequently, a catheter was inserted, with an initial unsuccessful removal 48 hours later, followed by a successful removal at 72 hours. A CT scan of his kidney, ureters, and bladder was performed to identify any structural causes of this gentleman&#x02019;s urinary retention but only showed a moderately enlarged prostate without obstructive lesions.</p><p>During his 72-hour hospital stay, he was treated with oral co-amoxiclav and clarithromycin and was discharged after symptom improvement. He was due to complete a full course of oral antibiotics with a repeat chest radiograph in primary care at six weeks post-discharge.</p><p>However, he re-presented to the emergency department seven days after initial discharge with worsening pain, restlessness, and weakness in his legs. The pain was described as aching and was concentrated in the thighs, with occasional transient pins and needles in his feet. Additionally, he reported unusual sensations on the left side of his face, including eye-watering and altered facial movement.</p><p>Neurological examination revealed bilateral lower motor neuron facial weakness with bilateral orbicularis oculi weakness, normal upper limb strength, and tone. Lower limb strength was decreased globally, proximally more so than distally, with reduced tone. Biceps, triceps, and brachioradialis reflexes were normal, with a notable reduction in the right knee reflex and absent ankle jerks. Pinprick, light touch, vibration sensation, and joint position sense were normal throughout the upper and lower limbs.</p><p>Cerebrospinal fluid (CSF) analysis (table <xref rid="TAB2" ref-type="table">2</xref>) showed elevated CSF protein (3.68 g/L), and a raised white cell count of 26/mm&#x000b3; (100% lymphocytes), with no bacterial growth.&#x000a0;A comprehensive viral panel (CSF viral PCR) was negative for herpes simplex virus (HSV), varicella-zoster virus (VZV), enterovirus, and parechovirus. Immune-related peripheral neuropathy screen was negative (table <xref rid="TAB3" ref-type="table">3</xref>).</p><table-wrap position="float" id="TAB2"><label>Table 2</label><caption><title>Cerebrospinal fluid analysis</title><p>HSV -&#x000a0;herpes simplex virus, VZV -&#x000a0;varicella-zoster virus</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Test&#x000a0;</td><td rowspan="1" colspan="1">Result&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Appearance</td><td rowspan="1" colspan="1">Clear, colorless fluid</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Opening pressure</td><td rowspan="1" colspan="1">18 cmH2O (10-20)</td></tr><tr><td rowspan="1" colspan="1">White blood cell count</td><td rowspan="1" colspan="1">26 per mm3&#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Polymorphs</td><td rowspan="1" colspan="1">0.0% No polymorphs</td></tr><tr><td rowspan="1" colspan="1">Lymphocytes</td><td rowspan="1" colspan="1">100.0%</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Red blood cell count</td><td rowspan="1" colspan="1">&#x0003c;1,000mm3</td></tr><tr><td rowspan="1" colspan="1">Gram stain</td><td rowspan="1" colspan="1">No organisms seen</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Culture</td><td rowspan="1" colspan="1">No growth</td></tr><tr><td rowspan="1" colspan="1">Protein</td><td rowspan="1" colspan="1">3.68 g/L (0.15-0.45)</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Lactate</td><td rowspan="1" colspan="1">2.1 mmol/L (1.1-2.4)</td></tr><tr><td rowspan="1" colspan="1">Oligoclonal bands</td><td rowspan="1" colspan="1">Negative (both serum and CSF)</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Parechovirus RNA</td><td rowspan="1" colspan="1">Not detected</td></tr><tr><td rowspan="1" colspan="1">HSV DNA</td><td rowspan="1" colspan="1">Not detected</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">VZV DNA</td><td rowspan="1" colspan="1">Not detected</td></tr><tr><td rowspan="1" colspan="1">Enterovirus RNA</td><td rowspan="1" colspan="1">Not detected</td></tr></tbody></table></table-wrap><table-wrap position="float" id="TAB3"><label>Table 3</label><caption><title>Peripheral neuropathy antibody screen</title></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Test</td><td rowspan="1" colspan="1">Result</td></tr><tr><td rowspan="1" colspan="1">IgG GM1 Ab level</td><td rowspan="1" colspan="1">Negative</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">IgM GM1 Ab level</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1">IgG GM2 Ab level</td><td rowspan="1" colspan="1">Negative</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">IgM GM2 Ab level</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1">IgG GD1a Ab level</td><td rowspan="1" colspan="1">Negative</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">IgM GD1a Ab level</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1">IgG GD1b Ab level</td><td rowspan="1" colspan="1">Negative</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">IgM GD1b Ab level</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1">IgG GQ1b Ab level</td><td rowspan="1" colspan="1">Negative</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">IgM GQ1b Ab level</td><td rowspan="1" colspan="1">Negative</td></tr></tbody></table></table-wrap><p>Non-contrast MRI&#x000a0;of the brain and the whole spine (Figures <xref rid="FIG3" ref-type="fig">3A</xref>-<xref rid="FIG3" ref-type="fig">3C</xref>) ruled out any underlying structural pathology.</p><fig position="anchor" fig-type="figure" id="FIG3"><label>Figure 3</label><caption><title>Normal magnetic resonance imaging of the patient's brain and spine, with no evidence of demyelination, hemorrhage, or infarct. (A) MRI head T2-weighted sequence, (B) MRI head susceptibility-weighted imaging (SWI) sequence, and (C) MRI spine.</title></caption><graphic xlink:href="cureus-0016-00000074657-i03" position="float"/></fig><p>Electromyography (EMG) undertaken 10 days following the onset of his neurological symptoms confirmed a pure-motor inflammatory demyelinating neuropathy (Tables <xref rid="TAB4" ref-type="table">4</xref>-<xref rid="TAB7" ref-type="table">7</xref>), characterized by delayed/absent blink reflexes and marked conduction slowing, with prolonged F-latency suggesting demyelination targets near the radicular level.</p><table-wrap position="float" id="TAB4"><label>Table 4</label><caption><title>Electromyography results</title></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Results</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Right orbicularis oculi</td><td rowspan="1" colspan="1">No spontaneous activity. Individual units of normal configuration. Units firing at high rates in relative isolation in a severely reduced interference pattern to 2mV.</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Right orbicularis oris</td><td rowspan="1" colspan="1">No spontaneous activity. Individual units of normal configuration. Units firing at high rates in relative isolation in a moderately reduced interference pattern to 2mV.</td></tr><tr><td rowspan="1" colspan="1">Right rectus femoris</td><td rowspan="1" colspan="1">No spontaneous activity. Individual units of normal configuration. Units firing at high rates in relative isolation in a moderately reduced interference pattern to 3mV.</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Right tibialis anterior</td><td rowspan="1" colspan="1">No spontaneous activity. Individual units of normal configuration. Units firing at high rates in relative isolation in a moderately reduced interference pattern to 3mV.</td></tr><tr><td rowspan="1" colspan="1">Right gastrocnemius (lateral head)</td><td rowspan="1" colspan="1">No spontaneous activity. Individual units of normal configuration. Units firing at high rates in relative isolation in a mildly reduced interference pattern to 3mV.</td></tr></tbody></table></table-wrap><table-wrap position="float" id="TAB5"><label>Table 5</label><caption><title>Facial/blink reflex study</title></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Reflex/laterality</td><td rowspan="1" colspan="1">Right</td><td rowspan="1" colspan="1">Left</td></tr><tr><td rowspan="1" colspan="1">Ipsilateral R1</td><td rowspan="1" colspan="1">17 ms</td><td rowspan="1" colspan="1">18 ms</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Ipsilateral R2</td><td rowspan="1" colspan="1">47 ms</td><td rowspan="1" colspan="1">0 ms</td></tr><tr><td rowspan="1" colspan="1">Contralateral R2</td><td rowspan="1" colspan="1">0 ms</td><td rowspan="1" colspan="1">0 ms</td></tr></tbody></table></table-wrap><table-wrap position="float" id="TAB6"><label>Table 6</label><caption><title>Sensory action potentials</title></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="2" colspan="1">Sensory action potentials</td><td rowspan="1" colspan="1">Amplitude</td><td rowspan="1" colspan="1">Conduction velocity</td></tr><tr><td rowspan="1" colspan="1">(&#x000b5;V)</td><td rowspan="1" colspan="1">(m/s)</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Right median (F2-wrist)</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">52</td></tr><tr><td rowspan="1" colspan="1">Right median (F3-wrist)</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">51</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Right ulnar (F5-wrist)</td><td rowspan="1" colspan="1">5.6</td><td rowspan="1" colspan="1">47</td></tr><tr><td rowspan="1" colspan="1">Right sural (calf-ankle)</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">51</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Right sup peroneal (calf-ankle)</td><td rowspan="1" colspan="1">3.8</td><td rowspan="1" colspan="1">42</td></tr></tbody></table></table-wrap><table-wrap position="float" id="TAB7"><label>Table 7</label><caption><title>Motor conduction velocities</title></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Median (stimulation electrode on abductor pollciis brevis)</td><td rowspan="1" colspan="1">Right</td></tr><tr><td rowspan="1" colspan="1">Distal motor latency</td><td rowspan="1" colspan="1">4.2 ms</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Conduction velocity (wrist-elbow)</td><td rowspan="1" colspan="1">43 m/s</td></tr><tr><td rowspan="1" colspan="1">Motor amplitude potential (wrist)</td><td rowspan="1" colspan="1">9.2 mV</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Motor amplitude potential (elbow)</td><td rowspan="1" colspan="1">7.6 mV</td></tr><tr><td rowspan="1" colspan="1">F latency</td><td rowspan="1" colspan="1">37 ms</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Ulnar (stimulation electrode on ADM)</td><td rowspan="1" colspan="1">Right</td></tr><tr><td rowspan="1" colspan="1">Distal motor latency</td><td rowspan="1" colspan="1">3.1 ms</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Conduction velocity (wrist-below elbow)</td><td rowspan="1" colspan="1">48 m/s</td></tr><tr><td rowspan="1" colspan="1">Conduction Velocity (around elbow)</td><td rowspan="1" colspan="1">48 m/s&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Motor amplitude potential (wrist)</td><td rowspan="1" colspan="1">10 mV</td></tr><tr><td rowspan="1" colspan="1">Motor amplitude potential (below elbow)</td><td rowspan="1" colspan="1">8.4 mV</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Motor amplitude potential (above elbow)</td><td rowspan="1" colspan="1">8.4 mV</td></tr><tr><td rowspan="1" colspan="1">F latency</td><td rowspan="1" colspan="1">39 ms</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Common peroneal (stimulation electrode on EDB)</td><td rowspan="1" colspan="1">Right</td></tr><tr><td rowspan="1" colspan="1">Distal motor latency</td><td rowspan="1" colspan="1">6.0 ms</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Conduction velocity (fib neck-ankle)</td><td rowspan="1" colspan="1">41 m/s</td></tr><tr><td rowspan="1" colspan="1">Motor amplitude potential (ankle)</td><td rowspan="1" colspan="1">1.6 mV</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Motor amplitude potential (fib neck)</td><td rowspan="1" colspan="1">1.6 mV</td></tr><tr><td rowspan="1" colspan="1">Posterior tibial (stimulation electrode on AH)</td><td rowspan="1" colspan="1">Right</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Distal motor latency</td><td rowspan="1" colspan="1">7.1 ms</td></tr><tr><td rowspan="1" colspan="1">Motor amplitude potential (ankle)</td><td rowspan="1" colspan="1">5.1 mV</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">F latency</td><td rowspan="1" colspan="1">76 ms</td></tr></tbody></table></table-wrap><p>Overall, his presentation, clinical examination findings, and investigations were felt to be consistent with a motor variant of GBS secondary to Mycoplasma infection.&#x000a0;A mildly raised CSF white cell count in GBS, though uncommon, has been documented in several studies.</p><p>The patient was closely monitored in an enhanced medical care unit and received a five-day course of intravenous immunoglobulin (IVIG). IVIG was commenced on day 10 since the onset of his neurological symptoms. His forced vital capacity (FVC) improved significantly from 2.08L to 4.93L indicating recovery in respiratory function. His FVC remained above the threshold for intubation and mechanical ventilation at all points during admission (1.4L, based on a threshold of 20mL/kg and a body weight of 69.1kg on admission). There was also no evidence of type two respiratory failure during his admission, as evidenced by blood gas testing.&#x000a0;On discharge, the patient had mild global weakness in his lower limbs with Medical Research Council (MRC) grade 4/5, and full power in the upper limbs but achieved full motor recovery over six months with physiotherapy.&#x000a0;</p></sec><sec sec-type="discussion"><title>Discussion</title><p>M. pneumoniae is a frequent cause of atypical pneumonia, with a spectrum of extra-pulmonary manifestations, with neurological sequelae being uncommon, particularly in adults [<xref rid="REF2" ref-type="bibr">2</xref>,<xref rid="REF3" ref-type="bibr">3</xref>,<xref rid="REF7" ref-type="bibr">7</xref>].&#x000a0;GBS classically presents with ascending weakness with a monophasic course - symmetry remains a key diagnostic feature [<xref rid="REF8" ref-type="bibr">8</xref>,<xref rid="REF9" ref-type="bibr">9</xref>]. The case we describe is typical in many ways; it presented shortly after the acute mycoplasma infection, with a delay of just days, and progressively worsened with no acute remission of symptoms, while producing an eventual bilateral, flaccid paralysis.&#x000a0;</p><p>However, several atypical clinical features were present that initially obscured our diagnosis and delayed the initiation of IVIG therapy. Notably, the erratic muscle involvement, particularly affecting the orbicularis oculi, initial asymmetry of patellar reflexes, and the atypical presenting complaint of restless legs were significant contributing factors to our diagnostic dilemma.</p><p>The epidemiological studies indicate the incidence of M. pneumoniae-associated GBS&#x000a0;and it was found that M. pneumoniae was detected in about 2%-5% of GBS cases [<xref rid="REF10" ref-type="bibr">10</xref>].&#x000a0;The mildly raised CSF pleocytosis was unusual but can occur in GBS&#x000a0;and was less than 50 cells [<xref rid="REF11" ref-type="bibr">11</xref>].</p><p>EMG and nerve conduction studies play a key role in confirming GBS - by identifying characteristic abnormalities like conduction block in demyelinating forms or reduced motor amplitudes in axonal variants [<xref rid="REF12" ref-type="bibr">12</xref>]. However, its diagnostic utility is time-sensitive, with EMG findings sometimes being normal within the first week of symptoms due to delayed onset of changes. Repeat testing is often necessary in cases of high clinical suspicion.</p><p>Our findings align with the diagnostic criteria for GBS as outlined by The European Academy of Neurology (EAN) and the Peripheral Nerve Society in their 2023 guidelines, as well as the Brighton Criteria developed in 2011, which helps stratify GBS diagnosis through clinical and testing criteria [<xref rid="REF8" ref-type="bibr">8</xref>,<xref rid="REF9" ref-type="bibr">9</xref>,<xref rid="REF13" ref-type="bibr">13</xref>]. The CSF analysis showing disproportionately elevated protein relative to the white cell count, and EMG findings of motor nerve demyelination, supported the diagnosis, in addition to the clinical findings present.</p><table-wrap position="float" id="TAB8"><label>Table 8</label><caption><title>Brighton Criteria for Diagnosis of GBS</title><p>+, present; -, absent; +/-, present or absent; GBS, Guillain-Barr&#x000e9;&#x000a0;syndrome; NCS, nerve conduction studies.&#x000a0;
*If CSF is not collected or results not available, nerve electrophysiology results must be consistent with the diagnosis of Guillain-&#x000a0;Barr&#x000e9;&#x000a0;syndrome. Level 1 is the highest level of diagnostic certainty; Level 4 is the lowest level of diagnostic certainty.&#x000a0;</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Diagnostic criteria</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">4</td></tr><tr><td rowspan="1" colspan="1">Bilateral and flaccid weakness of limbs</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+/-</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Decreased or absent deep tendon reflexes in weak limbs</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+/-</td></tr><tr><td rowspan="1" colspan="1">Monophasic course and time between onset-nadir 12 h to 28 days</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+/-</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">CSF cell count &#x0003c; 50/ &#x003bc;l</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+*</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">+/-</td></tr><tr><td rowspan="1" colspan="1">CSF protein concentration &#x0003e; normal value</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+/-*</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">+/-</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">NSC findings consistent with one of the subtypes of GBS</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+/-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">+/-</td></tr><tr><td rowspan="1" colspan="1">Absence of alternative diagnosis for weakness</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">+</td></tr></tbody></table></table-wrap><p>An interesting point of note in our case is the initial presentation with urinary retention - autonomic dysfunction is considered a supporting feature of GBS diagnosis within the 2023 guidelines, and a case series of 65 patients in Japan in 2009 showed that almost a third of their patients had urinary dysfunction, and almost 10% exhibited urinary retention [<xref rid="REF9" ref-type="bibr">9</xref>,<xref rid="REF14" ref-type="bibr">14</xref>].&#x000a0;</p><p>Spirometry remains an essential tool for the monitoring of GBS, especially with the risk of respiratory muscle involvement, with systematic reviews showing a relationship between spirometry and the need for ventilation, although there is limited evidence for specific thresholds [<xref rid="REF15" ref-type="bibr">15</xref>]. In the United Kingdom, we often use an FVC threshold of below 20mL/kg of body weight to guide the need for intubation with mechanical ventilation. Serial single breath counting has also been found to be a useful and cost-effective monitoring tool when used as a surrogate marker [<xref rid="REF16" ref-type="bibr">16</xref>]. Respiratory failure requires the need for specialist intensive care or high dependency input for consideration of mechanical ventilation modalities [<xref rid="REF9" ref-type="bibr">9</xref>,<xref rid="REF17" ref-type="bibr">17</xref>].&#x000a0;</p><p>The prognosis of GBS varies greatly, with around one-third of patients having incomplete recovery, with high age of onset and diarrhea preceding onset both being associated with a lower rate of independent walking at various time frames up to six months [<xref rid="REF9" ref-type="bibr">9</xref>,<xref rid="REF18" ref-type="bibr">18</xref>].&#x000a0;IVIG and plasma exchange are both treatments available that have been shown to reduce disability after a month of symptom onset [<xref rid="REF9" ref-type="bibr">9</xref>,<xref rid="REF19" ref-type="bibr">19</xref>].&#x000a0;The prognosis of mycoplasma-induced GBS compared to other causes of GBS is not well studied.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>This case illustrates the potential for neurological complications arising from M. pneumoniae infections, specifically the occurrence of GBS. The atypical presentation, including leg pain without weakness, urinary retention, and facial involvement, underscores the necessity for awareness among&#x000a0;clinicians regarding the spectrum of complications following Mycoplasma infections. Timely recognition, investigations, and appropriate treatment, such as IVIG, can lead to favorable outcomes. Further investigation is needed into the prognostication of mycoplasma-associated GBS compared to other causes of the syndrome.</p></sec></body><back><ack><p>Anush Shashidhara and Sithu Bala contributed equally to the work.</p></ack><fn-group content-type="conflict"><title>Disclosures</title><fn fn-type="COI-statement"><p><bold>Human subjects:</bold> Consent for treatment and open access publication was obtained or waived by all participants in this study.</p><p><bold>Conflicts of interest:</bold> In compliance with the ICMJE uniform disclosure form, all authors declare the following:</p><p><bold>Payment/services info:</bold> All authors have declared that no financial support was received from any organization for the submitted work.</p><p><bold>Financial relationships:</bold> All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.</p><p><bold>Other relationships:</bold> All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</p></fn></fn-group><fn-group content-type="other"><title>Author Contributions</title><fn fn-type="other"><p><bold>Concept and design:</bold>&#x000a0; Anush K. Shashidhara, Sithu Bala</p><p><bold>Acquisition, analysis, or interpretation of data:</bold>&#x000a0; Anush K. Shashidhara, Sithu Bala, Stefan Browne, Michael Cliff, Patrick Mallia</p><p><bold>Drafting of the manuscript:</bold>&#x000a0; Anush K. Shashidhara, Sithu Bala, Stefan Browne</p><p><bold>Critical review of the manuscript for important intellectual content:</bold>&#x000a0; Anush K. Shashidhara, Sithu Bala, Stefan Browne, Michael Cliff, Patrick Mallia</p><p><bold>Supervision:</bold>&#x000a0; Anush K. Shashidhara, Sithu Bala, Stefan Browne, Michael Cliff, Patrick Mallia</p></fn></fn-group><ref-list><title>References</title><ref id="REF1"><label>1</label><element-citation publication-type="webpage"><article-title>Pathogenesis of Mycoplasma pneumoniae: an update</article-title><date-in-citation content-type="access-date">
<month>11</month>
<year>2024</year>
</date-in-citation><year>2024</year><uri xlink:href="https://www.sciencedirect.com/science/article/pii/S0255085720300311">https://www.sciencedirect.com/science/article/pii/S0255085720300311</uri></element-citation></ref><ref id="REF2"><label>2</label><element-citation publication-type="journal"><article-title>Mycoplasma pneumoniae epidemiology in England and Wales: a national perspective</article-title><source>Front Microbiol</source><person-group>
<name><surname>Brown</surname><given-names>RJ</given-names></name>
<name><surname>Nguipdop-Djomo</surname><given-names>P</given-names></name>
<name><surname>Zhao</surname><given-names>H</given-names></name>
<name><surname>Stanford</surname><given-names>E</given-names></name>
<name><surname>Spiller</surname><given-names>OB</given-names></name>
<name><surname>Chalker</surname><given-names>VJ</given-names></name>
</person-group><fpage>157</fpage><volume>7</volume><year>2016</year><pub-id pub-id-type="pmid">26909073</pub-id>
</element-citation></ref><ref id="REF3"><label>3</label><element-citation publication-type="journal"><article-title>Classification of extrapulmonary manifestations due to Mycoplasma pneumoniae infection on the basis of possible pathogenesis</article-title><source>Front Microbiol</source><person-group>
<name><surname>Narita</surname><given-names>M</given-names></name>
</person-group><fpage>23</fpage><volume>7</volume><year>2016</year><pub-id pub-id-type="pmid">26858701</pub-id>
</element-citation></ref><ref id="REF4"><label>4</label><element-citation publication-type="journal"><article-title>Guillain-Barr&#x000e9; syndrome</article-title><source>Lancet</source><person-group>
<name><surname>Willison</surname><given-names>HJ</given-names></name>
<name><surname>Jacobs</surname><given-names>BC</given-names></name>
<name><surname>Doorn PA</surname><given-names>van</given-names></name>
</person-group><fpage>717</fpage><lpage>727</lpage><volume>388</volume><year>2016</year><pub-id pub-id-type="pmid">26948435</pub-id>
</element-citation></ref><ref id="REF5"><label>5</label><element-citation publication-type="journal"><article-title>Patterns in axonal and demyelinating subtypes of Guillain-Barr&#x000e9; syndrome</article-title><source>Neurology</source><person-group>
<name><surname>Mai</surname><given-names>P</given-names></name>
<name><surname>Saini</surname><given-names>P</given-names></name>
<name><surname>Zeidman</surname><given-names>L</given-names></name>
<name><surname>Schneck</surname><given-names>M</given-names></name>
</person-group><fpage>2829</fpage><volume>96</volume><year>2021</year></element-citation></ref><ref id="REF6"><label>6</label><element-citation publication-type="journal"><article-title>Mimics and chameleons in Guillain-Barr&#x000e9; and Miller Fisher syndromes</article-title><source>Pract Neurol</source><person-group>
<name><surname>Wakerley</surname><given-names>BR</given-names></name>
<name><surname>Yuki</surname><given-names>N</given-names></name>
</person-group><fpage>90</fpage><lpage>99</lpage><volume>15</volume><year>2015</year><pub-id pub-id-type="pmid">25239628</pub-id>
</element-citation></ref><ref id="REF7"><label>7</label><element-citation publication-type="journal"><article-title>Mycoplasma pneumoniae triggering the Guillain-Barr&#x000e9; syndrome: a case-control study</article-title><source>Ann Neurol</source><person-group>
<name><surname>Meyer Sauteur</surname><given-names>PM</given-names></name>
<name><surname>Huizinga</surname><given-names>R</given-names></name>
<name><surname>Tio-Gillen</surname><given-names>AP</given-names></name>
<etal/>
</person-group><fpage>566</fpage><lpage>580</lpage><volume>80</volume><year>2016</year><pub-id pub-id-type="pmid">27490360</pub-id>
</element-citation></ref><ref id="REF8"><label>8</label><element-citation publication-type="journal"><article-title>Diagnosis of Guillain-Barr&#x000e9; syndrome and validation of Brighton criteria</article-title><source>Brain</source><person-group>
<name><surname>Fokke</surname><given-names>C</given-names></name>
<name><surname>van den Berg</surname><given-names>B</given-names></name>
<name><surname>Drenthen</surname><given-names>J</given-names></name>
<name><surname>Walgaard</surname><given-names>C</given-names></name>
<name><surname>van Doorn</surname><given-names>PA</given-names></name>
<name><surname>Jacobs</surname><given-names>BC</given-names></name>
</person-group><fpage>33</fpage><lpage>43</lpage><volume>137</volume><year>2014</year><pub-id pub-id-type="pmid">24163275</pub-id>
</element-citation></ref><ref id="REF9"><label>9</label><element-citation publication-type="journal"><article-title>European Academy of Neurology/peripheral nerve Society guideline on diagnosis and treatment of Guillain-Barr&#x000e9; syndrome</article-title><source>Eur J Neurol</source><person-group>
<name><surname>van Doorn</surname><given-names>PA</given-names></name>
<name><surname>Van den Bergh</surname><given-names>PY</given-names></name>
<name><surname>Hadden</surname><given-names>RD</given-names></name>
<etal/>
</person-group><fpage>3646</fpage><lpage>3674</lpage><volume>30</volume><year>2023</year><pub-id pub-id-type="pmid">37814552</pub-id>
</element-citation></ref><ref id="REF10"><label>10</label><element-citation publication-type="journal"><article-title>The spectrum of antecedent infections in Guillain-Barr&#x000e9; syndrome: a case-control study</article-title><source>Neurology</source><person-group>
<name><surname>Jacobs</surname><given-names>BC</given-names></name>
<name><surname>Rothbarth</surname><given-names>PH</given-names></name>
<name><surname>van der Mech&#x000e9;</surname><given-names>FG</given-names></name>
<name><surname>Herbrink</surname><given-names>P</given-names></name>
<name><surname>Schmitz</surname><given-names>PI</given-names></name>
<name><surname>de Klerk</surname><given-names>MA</given-names></name>
<name><surname>van Doorn</surname><given-names>PA</given-names></name>
</person-group><fpage>1110</fpage><lpage>1115</lpage><volume>51</volume><year>1998</year><pub-id pub-id-type="pmid">9781538</pub-id>
</element-citation></ref><ref id="REF11"><label>11</label><element-citation publication-type="journal"><article-title>Guillain-Barr&#x000e9; syndrome with marked pleocytosis or a significant proportion of polymorphonuclear granulocytes in the cerebrospinal fluid: neuropathological investigation of five cases and review of differential diagnoses</article-title><source>Eur J Neurol</source><person-group>
<name><surname>Rauschka</surname><given-names>H</given-names></name>
<name><surname>Jellinger</surname><given-names>K</given-names></name>
<name><surname>Lassmann</surname><given-names>H</given-names></name>
<name><surname>Braier</surname><given-names>F</given-names></name>
<name><surname>Schmidbauer</surname><given-names>M</given-names></name>
</person-group><fpage>479</fpage><lpage>486</lpage><volume>10</volume><year>2003</year><pub-id pub-id-type="pmid">12940826</pub-id>
</element-citation></ref><ref id="REF12"><label>12</label><element-citation publication-type="journal"><article-title>Changes in electrophysiological findings suggestive of demyelination following Guillain-Barr&#x000e9; syndrome: a retrospective study</article-title><source>Muscle Nerve</source><person-group>
<name><surname>Gu&#x000e9;my</surname><given-names>C</given-names></name>
<name><surname>Durand</surname><given-names>MC</given-names></name>
<name><surname>Brisset</surname><given-names>M</given-names></name>
<name><surname>Nicolas</surname><given-names>G</given-names></name>
</person-group><fpage>394</fpage><lpage>400</lpage><volume>67</volume><year>2023</year><pub-id pub-id-type="pmid">36814082</pub-id>
</element-citation></ref><ref id="REF13"><label>13</label><element-citation publication-type="journal"><article-title>Guillain-Barr&#x000e9; syndrome in India: population-based validation of the Brighton criteria</article-title><source>Vaccine</source><person-group>
<name><surname>Mateen</surname><given-names>FJ</given-names></name>
<name><surname>Cornblath</surname><given-names>DR</given-names></name>
<name><surname>Jafari</surname><given-names>H</given-names></name>
<etal/>
</person-group><fpage>9697</fpage><lpage>9701</lpage><volume>29</volume><year>2011</year><pub-id pub-id-type="pmid">22001121</pub-id>
</element-citation></ref><ref id="REF14"><label>14</label><element-citation publication-type="journal"><article-title>Prevalence and mechanism of bladder dysfunction in Guillain-Barr&#x000e9; syndrome</article-title><source>Neurourol Urodyn</source><person-group>
<name><surname>Sakakibara</surname><given-names>R</given-names></name>
<name><surname>Uchiyama</surname><given-names>T</given-names></name>
<name><surname>Kuwabara</surname><given-names>S</given-names></name>
<etal/>
</person-group><fpage>432</fpage><lpage>437</lpage><volume>28</volume><year>2009</year><pub-id pub-id-type="pmid">19260087</pub-id>
</element-citation></ref><ref id="REF15"><label>15</label><element-citation publication-type="journal"><article-title>A vital parameter? Systematic review of spirometry in evaluation for intensive care unit admission and intubation and ventilation for Guillain-Barr&#x000e9; syndrome</article-title><source>J Clin Neurosci</source><person-group>
<name><surname>Madike</surname><given-names>R</given-names></name>
<name><surname>Muecke</surname><given-names>T</given-names></name>
<name><surname>Dishnica</surname><given-names>N</given-names></name>
<etal/>
</person-group><fpage>13</fpage><lpage>19</lpage><volume>113</volume><year>2023</year><pub-id pub-id-type="pmid">37146475</pub-id>
</element-citation></ref><ref id="REF16"><label>16</label><element-citation publication-type="journal"><article-title>Serial single breath count is a reliable tool for monitoring respiratory functions in Guillain-Barr&#x000e9; syndrome</article-title><source>J Clin Neurosci</source><person-group>
<name><surname>Kalita</surname><given-names>J</given-names></name>
<name><surname>Kumar</surname><given-names>M</given-names></name>
<name><surname>Misra</surname><given-names>UK</given-names></name>
</person-group><fpage>50</fpage><lpage>56</lpage><volume>72</volume><year>2020</year><pub-id pub-id-type="pmid">31982274</pub-id>
</element-citation></ref><ref id="REF17"><label>17</label><element-citation publication-type="journal"><article-title>Mechanical ventilation in Guillain-Barr&#x000e9; syndrome</article-title><source>Expert Rev Clin Immunol</source><person-group>
<name><surname>Shang</surname><given-names>P</given-names></name>
<name><surname>Zhu</surname><given-names>M</given-names></name>
<name><surname>Baker</surname><given-names>M</given-names></name>
<name><surname>Feng</surname><given-names>J</given-names></name>
<name><surname>Zhou</surname><given-names>C</given-names></name>
<name><surname>Zhang</surname><given-names>HL</given-names></name>
</person-group><fpage>1053</fpage><lpage>1064</lpage><volume>16</volume><year>2020</year><pub-id pub-id-type="pmid">33112177</pub-id>
</element-citation></ref><ref id="REF18"><label>18</label><element-citation publication-type="journal"><article-title>Early recognition of poor prognosis in Guillain-Barre syndrome</article-title><source>Neurology</source><person-group>
<name><surname>Walgaard</surname><given-names>C</given-names></name>
<name><surname>Lingsma</surname><given-names>HF</given-names></name>
<name><surname>Ruts</surname><given-names>L</given-names></name>
<name><surname>van Doorn</surname><given-names>PA</given-names></name>
<name><surname>Steyerberg</surname><given-names>EW</given-names></name>
<name><surname>Jacobs</surname><given-names>BC</given-names></name>
</person-group><fpage>968</fpage><lpage>975</lpage><volume>76</volume><year>2011</year><pub-id pub-id-type="pmid">21403108</pub-id>
</element-citation></ref><ref id="REF19"><label>19</label><element-citation publication-type="journal"><article-title>Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barr&#x000e9; syndrome</article-title><source>Lancet</source><fpage>225</fpage><lpage>230</lpage><volume>349</volume><year>1997</year><pub-id pub-id-type="pmid">9014908</pub-id>
</element-citation></ref></ref-list></back></article>